Zobrazeno 1 - 10
of 36
pro vyhledávání: '"S. Greenbloom"'
Autor:
Federico J. Mensa, Fred Poordad, Tami Pilot-Matias, Magdy Elkhashab, Neddie Zadeikis, Albert Tran, Carolyn M. Setze, Catherine A.M. Stedman, Ariel Porcalla, Marcus A. Wörns, Yao Yu, Stanley Wang, Joaquin Mario Valdes, S. Greenbloom, T. Nguyen, C.-W. Lin, Jean-Pierre Mulkay, Armen Asatryan, Wei Liu, Edward Gane
Publikováno v:
Clinical infectious diseases, 69 (10
Background: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-f
Autor:
James O. Lindsay, M A Weinreich, Remo Panaccione, Silvio Danese, G. D'Haens, Wangang Xie, Pascal Juillerat, W J Sandborn, Wen Zhou, Y. Sanchez Gonzalez, Aileen L. Pangan, Walter Reinisch, Bidan Huang, Julià Panés, Severine Vermeire, Edward V. Loftus, S Greenbloom, J Liu
Publikováno v:
Journal of Crohn's & Colitis
Background Upadacitinib (UPA) is a selective and reversible Janus kinase inhibitor.U-ACCOMPLISH is one of two phase 3 induction trials that evaluated the safety and efficacy of UPA 45 mg once daily (QD) in adults with ulcerative colitis (UC). Methods
Autor:
Julià Panés, Qian Zhou, L Peyrin-Biroulet, Wen Zhou, Ana P. Lacerda, Edouard Louis, J Liu, W J Sandborn, S Greenbloom
Publikováno v:
Journal of Crohn's and Colitis. 14:S117-S118
Background Patients with Crohn’s disease (CD) may lose response to treatment, requiring dose adjustments. This analysis from the CELEST study evaluated efficacy and safety in patients with CD who required an escalated dose of upadacitinib (UPA), an
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Curtis Cooper, S. Greenbloom, Magdy Elkashab, Nabil Abadir, Nir Hilzenrat, Kurt E. Williams, John Farley, Stephen D. Shafran, Robert Enns, Manuela G. Neuman
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 28, Iss 1, Pp 35-40 (2014)
BACKGROUND: Serum tumour necrosis factor-alpha (TNF-α) levels correlate negatively with hepatitis C virus (HCV) antiviral response.OBJECTIVES: To test the hypothesis that a single infliximab induction dose would positively influence on-treatment vir
Autor:
Jordan J. Feld, Emmanuelle Huchet, S. Greenbloom, Evguenia S. Svarovskaia, Diana M. Brainard, K.C. Huang, Curtis Cooper, Stephen D. Shafran, Paul Marotta, Marie-Louise Vachon, Robert C. Bailey, Sergio Borgia, Alnoor Ramji, Eric M. Yoshida, Magdy Elkhashab, Robert H. Hyland, Benedetta Massetto, John G. McHutchison, Chohee Yun, Mark G. Swain, Bernard Willems, Edward Tam
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 65(1)
Background Patients chronically infected with genotype 3 hepatitis C virus (HCV) have faster disease progression and are less responsive to current direct-acting antiviral regimens than patients infected with other genotypes. We conducted an open-lab
Autor:
Carla S. Coffin, Nezam H. Afdhal, Radhakrishnan P. Iyer, Kathy Jackson, Young-Suk Lim, Kwan Sik Lee, Yoon Jun Kim, Henry Chan, Dong Joon Kim, Scott Fung, RachelWen-Juei Jeng, Alnoor Ramji, S. Greenbloom, Magdy Elkashab, J.W. Jang, Won Kim, C Macfarlane, C. Y. Chen, Stephen Locarnini, Man-Fung Yuen
Publikováno v:
Journal of Hepatology. 68:S509-S510
Autor:
S. Greenbloom, S. S. Lee, Robert Balshaw, Nir Hilzenrat, Morris Sherman, Magdy Elkashab, Alnoor Ramji, H. Pluta, Christopher Usaty, Robert P. Myers
Publikováno v:
Alimentary Pharmacology & Therapeutics. 35:37-47
Aliment Pharmacol Ther 2012; 35: 37–47 Summary Background The efficacy of individualised antiviral treatment durations for chronic hepatitis C remains unclear. Aim To evaluate treatment durations based on virological responses at week 4, 8 and 12 o
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.